
    
      To assess the effect of Aranesp_ on the hemoglobin (Hgb) of CRI subjects who are recombinant
      human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy. To assess the
      association between subject self-reported health-related quality of life (HRQoL) as it
      relates to Hgb concentration and glomerular filtration rate (GFR) in subjects who were
      rHuEPO-naïve prior to study enrollment. To characterize the health-related resource
      utilization of subjects with CRI. To characterize the subject satisfaction with Aranesp_
      compared to previous rHuEPO therapy. To characterize iron treatment in subjects with CRI. To
      assess the safety profile of Aranesp_ therapy in subjects with CRI
    
  